US2018000807A1PendingUtilityA1

Selective nr2b antagonists

Assignee: BRISTOL MYERS SQUIBB COPriority: Jan 9, 2014Filed: Sep 15, 2017Published: Jan 4, 2018
Est. expiryJan 9, 2034(~7.5 yrs left)· nominal 20-yr term from priority
A61P 25/28A61P 25/16A61P 25/24A61P 25/04A61P 25/02A61P 25/00C07D 403/04A61K 31/454C07D 401/04
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . A pharmaceutical composition comprising the compound (R)-3-((3S,4S)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2018000807A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.